Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial-Reference-Cited by-同舟云学术

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial

Published:2006-12-12 Issue:1 Volume:96 Page:21-28
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Barone C,Landriscina M,Quirino M,Basso M,Pozzo C,Schinzari G,Leonardo G Di,D'Argento E,Trigila N,Cassano A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603496.pdf

Reference32 articles.

1. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343–1347

2. Atalay G, Cardoso F, Paesmans M, Goldberg RM, Bleiberg H (2003) Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice? Anticancer Drugs 14: 703–713

3. Chou TC, Motzer RJ, Tong V, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rationale approach to clinical protocol design. J Natl Cancer Inst 86: 1517–1524

4. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55

5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041–1047

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis;Aging;2023-05-09

2. Design of robust control strategy in drug and virus scheduling in nonlinear process of chemovirotherapy;Computers & Chemical Engineering;2021-07

3. NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression;International Journal of Molecular Sciences;2020-06-30

4. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells;Cancer Letters;2018-10

5. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells;Biological & Pharmaceutical Bulletin;2017